Amanta Healthcare Ltd is Rated Sell

Current Rating and Its Significance

The current Sell rating assigned to Amanta Healthcare Ltd indicates a cautious stance for investors. This rating suggests that the stock is expected to underperform relative to the broader market or its sector peers in the near to medium term. Investors should consider this recommendation carefully, as it reflects a combination of the company’s fundamental health, valuation, financial trends, and technical outlook as of today.

Quality Assessment

As of 08 August 2026, Amanta Healthcare’s quality grade is assessed as below average. This evaluation stems from the company’s weak long-term fundamental strength. Over the past five years, the company has achieved a modest compound annual growth rate (CAGR) of 9.30% in operating profits, which is relatively low for the Pharmaceuticals & Biotechnology sector. Additionally, the company’s ability to service its debt remains a concern, with an average EBIT to interest coverage ratio of just 1.30, indicating limited buffer to meet interest obligations comfortably.

Return on equity (ROE) averages 8.18%, signalling low profitability per unit of shareholders’ funds. This level of return is below what many investors would expect from a growth-oriented healthcare company, reflecting challenges in generating strong earnings relative to equity invested.

Valuation Perspective

Despite the quality concerns, the valuation grade for Amanta Healthcare Ltd is currently attractive. This suggests that the stock is trading at a price level that may offer value relative to its earnings potential and asset base. For value-focused investors, this could present an opportunity to acquire shares at a discount compared to intrinsic worth or sector averages. However, valuation alone does not offset the risks posed by weak fundamentals and financial trends.

Financial Trend Analysis

The financial trend for Amanta Healthcare is rated negative as of today. Recent quarterly results highlight some troubling signs. The company reported a significant increase in interest expenses, with interest costs rising by 41.18% to ₹6.00 crores in the latest quarter. Meanwhile, profit after tax (PAT) declined by 18.7% to ₹3.31 crores compared to the previous four-quarter average. Earnings before depreciation, interest, and taxes (PBDIT) also hit a low of ₹14.54 crores, underscoring margin pressures and operational challenges.

These figures indicate deteriorating profitability and rising financial costs, which weigh heavily on the company’s overall financial health and future earnings potential.

Technical Outlook

From a technical standpoint, the stock exhibits a mildly bullish trend. Despite recent price declines, including a 1-day drop of 1.97% and a 1-month decline of 8.57%, the stock has shown resilience over longer periods. It has delivered a 3-month gain of 21.56%, a 6-month surge of 60.03%, and a year-to-date return of 53.04%. This suggests that while short-term momentum is weak, there remains some underlying buying interest and potential for recovery in the medium term.